Atteinte intrathoracique au cours de la polyarthrite rhumatoïde: à propos de 45 cas
O. Beyne-Rauzy(Hôpital Rangueil), P. Arlet(Hôpital Rangueil), M. Carreiro, S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), María Jesús Moro Álvarez(Hôpital Rangueil), L. Astudillo(Hôpital Purpan), H. Juchet(Hôpital Rangueil), M Ecoiffier, C. Dingremont(Hôpital Rangueil)
Cited by 0
Related Papers
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults
|Journal of Thrombosis and Haemostasis|2018|138
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
|Nature Medicine|2024|109
Acute interstitial nephritis related to immune checkpoint inhibitors
|British Journal of Cancer|2016|103